While the CD44 isoform-specific antibodies for immunohistochemistry could identify cells in situ that express a specific isoform, the employment of transcript-specific primers on bulk tumor RNA could quantify each transcript level but could not distinguish the cell type (tumor or normal) that expressed a specific CD44 isoform. This evidence concerns the gene CD44 and neoplasm.